Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455467 | 0.89 | MAPT (0.72) | KDM4EMAPTALDH1A1HPGDLMNA | |
| SCHEMBL1454579 | 0.86 | MAPT (0.58) | KDM4EMAPTALDH1A1HPGDLMNA | |
| SCHEMBL1455205 | 0.85 | MAPT (0.46) | KDM4EMAPTALDH1A1HPGDLMNA | |
| SCHEMBL13305748 | 0.85 | MAP4K4 (0.53) | KDM4EMAPTALDH1A1HPGDLMNA | |
| SCHEMBL1454638 | 0.83 | MAPT (0.52) | KDM4EMAPTALDH1A1HPGDLMNA | |
| SCHEMBL5013979 | 0.81 | MAPT (0.67) | KDM4EMAPTALDH1A1HPGDLMNA | |
| SCHEMBL15912554 | 0.81 | MAPT (0.51) | KDM4EMAPTALDH1A1HPGDLMNA | |
| SCHEMBL1455518 | 0.81 | NAMPT (0.46) | KDM4EMAPTALDH1A1HPGDLMNA | |
| SCHEMBL1456099 | 0.80 | MEN1 (0.42) | KDM4EMAPTALDH1A1HPGDLMNA | |
| SCHEMBL1456097 | 0.80 | MEN1 (0.42) | KDM4EMAPTALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367824-B1 | Anti-viral derivatives of pyrimidine | ABBVIE INC (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2367824-B1 | Anti-viral derivatives of pyrimidine | ABBVIE INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9249138-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249138-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249138-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9163017-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163017-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163017-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140213601-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213601-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2010075380-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075376-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075380-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160355-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160355-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160355-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KDM4E 2318/4885MAPT 2833/4885ALDH1A1 2858/4885 |
| US-20140213601-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM4E 2318/4885MAPT 2833/4885ALDH1A1 2858/4885 |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KDM4E 1822/4885MAPT 1347/4885ALDH1A1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.